NO993275L - Fremgangsmåte ved terapeutisk administrering av anti-CD40L-forbindelser - Google Patents

Fremgangsmåte ved terapeutisk administrering av anti-CD40L-forbindelser

Info

Publication number
NO993275L
NO993275L NO993275A NO993275A NO993275L NO 993275 L NO993275 L NO 993275L NO 993275 A NO993275 A NO 993275A NO 993275 A NO993275 A NO 993275A NO 993275 L NO993275 L NO 993275L
Authority
NO
Norway
Prior art keywords
therapeutic administration
cd40l compounds
cd40l
compounds
administering anti
Prior art date
Application number
NO993275A
Other languages
English (en)
Norwegian (no)
Other versions
NO993275D0 (no
Inventor
Susan L Kalled
David W Thomas
Original Assignee
Biogen Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Biogen Inc filed Critical Biogen Inc
Publication of NO993275D0 publication Critical patent/NO993275D0/no
Publication of NO993275L publication Critical patent/NO993275L/no

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2875—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the NGF/TNF superfamily, e.g. CD70, CD95L, CD153, CD154
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Microbiology (AREA)
  • Transplantation (AREA)
  • Mycology (AREA)
  • Epidemiology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Steroid Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
NO993275A 1997-01-10 1999-07-01 Fremgangsmåte ved terapeutisk administrering av anti-CD40L-forbindelser NO993275L (no)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US3467297P 1997-01-10 1997-01-10
US4015497P 1997-03-07 1997-03-07
PCT/US1998/000573 WO1998030241A1 (en) 1997-01-10 1998-01-09 Methods of therapeutic administration of anti-cd40l compounds

Publications (2)

Publication Number Publication Date
NO993275D0 NO993275D0 (no) 1999-07-01
NO993275L true NO993275L (no) 1999-09-09

Family

ID=26711241

Family Applications (1)

Application Number Title Priority Date Filing Date
NO993275A NO993275L (no) 1997-01-10 1999-07-01 Fremgangsmåte ved terapeutisk administrering av anti-CD40L-forbindelser

Country Status (21)

Country Link
US (2) US20020071840A1 (ja)
EP (1) EP0966302B1 (ja)
JP (1) JP2001508450A (ja)
KR (2) KR100632846B1 (ja)
CN (1) CN1248921A (ja)
AT (1) ATE356634T1 (ja)
AU (1) AU721697B2 (ja)
BR (1) BR9807471A (ja)
CA (1) CA2277223A1 (ja)
CZ (1) CZ244399A3 (ja)
DE (1) DE69837322T2 (ja)
EA (1) EA001426B1 (ja)
EE (1) EE9900275A (ja)
HK (1) HK1024424A1 (ja)
IL (1) IL130785A0 (ja)
IS (1) IS5101A (ja)
NO (1) NO993275L (ja)
NZ (1) NZ337073A (ja)
PL (1) PL193966B1 (ja)
TR (1) TR199902192T2 (ja)
WO (1) WO1998030241A1 (ja)

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5474771A (en) 1991-11-15 1995-12-12 The Trustees Of Columbia University In The City Of New York Murine monoclonal antibody (5c8) recognizes a human glycoprotein on the surface of T-lymphocytes, compositions containing same
US7070777B1 (en) 1991-11-15 2006-07-04 The Trustees Of Columbia University In The City Of New York Method for inhibiting inflammation with an antibody that binds the 5C8 protein
US6340459B1 (en) 1995-12-01 2002-01-22 The Trustees Of Columbia University In The City Of New York Therapeutic applications for the anti-T-BAM (CD40-L) monoclonal antibody 5C8 in the treatment of reperfusion injury in non-transplant recipients
CA2291156A1 (en) * 1997-05-17 1998-11-26 Biogen, Inc. Use of a cd40:cd154 binding interruptor to prevent counter adaptive immune responses, particularly graft rejection
NZ502051A (en) * 1997-06-20 2001-04-27 Biogen Inc CD154 blockade therapy for therapeutic protein inhibitor syndrome
IL142069A0 (en) * 1998-09-21 2002-03-10 Genetics Inst Methods of downmodulating the immune response to therapeutic proteins
WO2000072882A1 (fr) * 1999-06-01 2000-12-07 Eisai Co., Ltd. Agents prophylactiques du purpura thrombocytopenique idiopathique
GB9927757D0 (en) * 1999-11-25 2000-01-26 Kennedy Rheumatology Inst Treatment of autoimmune diseases
EP1262194A4 (en) * 2000-03-06 2003-05-07 Eisai Co Ltd HEALING AND PREVENTIVE AGENTS FOR THE ANTIPHOSPHOLIPID-ANTIBODY SYNDROME
AU2001251612A1 (en) 2000-04-14 2001-10-30 Millennium Pharmaceuticals, Inc. Roles of jak/stat family members in tolerance induction
US20030059427A1 (en) * 2000-04-28 2003-03-27 Force Walker R. Isolation and characterization of highly active anti-CD40 antibody
EP1294699B1 (en) 2000-05-12 2016-04-13 Genzyme Corporation Modulators of tnf- alpha signalling
JP3785508B2 (ja) * 2002-04-15 2006-06-14 学校法人慶應義塾 遺伝子治療における免疫応答を解析できる実験モデルマウス
JP4914008B2 (ja) * 2002-11-21 2012-04-11 ジェンザイム・コーポレーション 免疫寛容を誘導するためのジアミド誘導体と免疫抑制剤との組み合わせ
ES2650267T3 (es) 2008-12-05 2018-01-17 Als Therapy Development Institute Método para el tratamiento de enfermedades neurodegenerativas

Family Cites Families (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5981724A (en) * 1991-10-25 1999-11-09 Immunex Corporation DNA encoding CD40 ligand, a cytokine that binds CD40
US5962406A (en) * 1991-10-25 1999-10-05 Immunex Corporation Recombinant soluble CD40 ligand polypeptide and pharmaceutical composition containing the same
US5961974A (en) * 1991-10-25 1999-10-05 Immunex Corporation Monoclonal antibodies to CD40 ligand, pharmaceutical composition comprising the same and hybridomas producing the same
US5474771A (en) * 1991-11-15 1995-12-12 The Trustees Of Columbia University In The City Of New York Murine monoclonal antibody (5c8) recognizes a human glycoprotein on the surface of T-lymphocytes, compositions containing same
US5397703A (en) * 1992-07-09 1995-03-14 Cetus Oncology Corporation Method for generation of antibodies to cell surface molecules
US5540926A (en) * 1992-09-04 1996-07-30 Bristol-Myers Squibb Company Soluble and its use in B cell stimulation
CN1127351C (zh) * 1993-09-02 2003-11-12 达特茅斯学院理事 诱导抗原特异性ｔ细胞耐受的方法
IL110852A (en) * 1993-09-02 1999-05-09 Dartmouth College Methods of prolonged suppression of humoral activity
ZA946765B (en) * 1993-09-02 1996-02-15 Dartmouth College Methods of prolonged suppression of humoral immunity
US5869049A (en) * 1993-09-02 1999-02-09 Trustees Of Dartmouth College Methods of inducing T cell unresponsiveness to bone marrow with gp39 antagonists
JPH09507074A (ja) * 1993-12-23 1997-07-15 イミュネックス・コーポレーション Ｃｄ４０を発現する腫瘍細胞を特徴とする疾患の予防又は治療方法
US5683693A (en) * 1994-04-25 1997-11-04 Trustees Of Dartmouth College Method for inducing T cell unresponsiveness to a tissue or organ graft with anti-CD40 ligand antibody or soluble CD40
US5876950A (en) * 1995-01-26 1999-03-02 Bristol-Myers Squibb Company Monoclonal antibodies specific for different epitopes of human GP39 and methods for their use in diagnosis and therapy
US5833987A (en) * 1995-06-07 1998-11-10 Trustees Of Dartmouth College Treatment of T cell mediated autoimmune disorders
US6001358A (en) * 1995-11-07 1999-12-14 Idec Pharmaceuticals Corporation Humanized antibodies to human gp39, compositions containing thereof
DK0892643T4 (da) * 1996-03-20 2009-12-14 Bristol Myers Squibb Co Fremgangsmåder til inhibering af et immunrespons ved blokering af GP39/CD40- og CTLA4/CD28/B7-banerne og præparater til anvendelse derved

Also Published As

Publication number Publication date
ATE356634T1 (de) 2007-04-15
JP2001508450A (ja) 2001-06-26
EE9900275A (et) 2000-02-15
KR20000070035A (ko) 2000-11-25
US20050158314A1 (en) 2005-07-21
PL334500A1 (en) 2000-02-28
WO1998030241A1 (en) 1998-07-16
KR20050088494A (ko) 2005-09-06
NZ337073A (en) 2001-01-26
EP0966302A1 (en) 1999-12-29
US20020071840A1 (en) 2002-06-13
NO993275D0 (no) 1999-07-01
AU5735398A (en) 1998-08-03
CZ244399A3 (cs) 1999-10-13
IS5101A (is) 1999-06-30
CA2277223A1 (en) 1998-07-16
HK1024424A1 (en) 2000-10-13
TR199902192T2 (xx) 1999-12-21
EP0966302B1 (en) 2007-03-14
PL193966B1 (pl) 2007-04-30
IL130785A0 (en) 2001-01-28
CN1248921A (zh) 2000-03-29
BR9807471A (pt) 2000-03-21
DE69837322T2 (de) 2007-11-22
KR100632846B1 (ko) 2006-10-16
AU721697B2 (en) 2000-07-13
EA001426B1 (ru) 2001-02-26
DE69837322D1 (de) 2007-04-26
EA199900633A1 (ru) 2000-02-28

Similar Documents

Publication Publication Date Title
NO993275L (no) Fremgangsmåte ved terapeutisk administrering av anti-CD40L-forbindelser
CY1118651T1 (el) Αζακυκλικες ενωσεις για χρηση στην θεραπευτικη αντιμετωπιση ασθενειων που σχετιζονται με τη σεροτονινη
BR9810841A (pt) Inibidores de metaloprotease alicìclicos
AP2004003069A0 (en) 3-beta-d-ribofuranosynthiazolo [4-5-d] pyridimine nucleosides and uses thereof.
ES2191069T3 (es) Diaril-2-(5h)-furanonas como inhibidores de cox-2.
ATE189218T1 (de) Bicyclische diarylheterocyclen als cyclooxygenase-2-inhibitoren
DK0900200T3 (da) Farmaceutiske sammensætninger til forebyggelse og behandling af sygdom i centralnervesystemet
LV12291A (lv) Savienojums un farmaceitiskas kompozicijas ar triptazes aktivitates izmainam saistitu slimibu arstesanai
DE69825154D1 (de) Pyridazinone als inhibitoren von cyclooxygenase-2
IL192287A0 (en) Pharmaceutical compositions and methods for use
NO20003313L (no) Terapeutiske midler
DE69625682T2 (de) Verfahren zur behandlung von entzündungen und zusammensetzungen dafür
HK1043315A1 (en) Triazineone compounds for treating diseases due tosarcosystis, neospora and toxoplasma.
DK1140103T3 (da) Ponazuril til behandling af neurologiske og abortfremkaldende sygdomme forårsaget af Coccidia
DE60306503D1 (de) Statin-therapie zur verbesserung der aufrechterhaltung der kognitiven funktion
HUP9903679A2 (hu) Olanzapin alkalmazása bipoláris zavar kezelésére szolgáló gyógyszerkészítmények előállítására
DE69829861D1 (de) 2-aminopyridine als inhibitoren von cyclooxygenase-2
ATE248607T1 (de) Aminotetralin derivate zur therapie der kardiovaskulären erkrankungen
EA199800941A1 (ru) Терапевтические средства, содержащие кислородные анион-радикалы и/или продукты их последующего превращения и расщепления, и их применение для лечения болезни паркинсона
MX9704887A (es) Composiciones farmaceuticas para el tratamiento de trastornos depresivos.
EA200200846A1 (ru) Соединения, полезные для лечения или предупреждения заболеваний, опосредуемых альфа-2в-адреноцептором
LV12459A (lv) Savienojums un farmaceitiskas kompozicijas ar triptazes aktivitates izmainam saistitu slimibu arstesanai

Legal Events

Date Code Title Description
FC2A Withdrawal, rejection or dismissal of laid open patent application